THURSDAY, SEPTEMBER 29, 2016

ViiV Healthcare presents results of drug combinations to treat HIV

ViiV Healthcare, a GlaxoSmithKline and Pfizer joint venture, presented on Tuesday the results of a phase III study on the combination of maraviroc with darunavir/ritonavir and emtricitabine/tenovfovir to treat HIV.

The double-blind study sought to discover whether a two-drug daily regimen of maraviroc and darunavir may provide comparable results compared to a three-drug regimen, GlaxoSmithKline (GSK) said in a press release.

Results from the study showed more maraviroc patients discontinued the two-drug treatment due to a lack of efficacy, and treatment failures occurred more often in the two-drug combination.

"Although this investigational two-drug regimen was inferior to the three-drug regimen in this study, maraviroc remains a valuable antiretroviral therapy when used in combination with other antiretrovirals and dosed twice daily in adults with confirmed CCR5-tropic HIV," John Pottage, the chief scientific and medical officer at ViiV Healthcare, said.

The company said it was committed to supporting programs that seek to understand the treatments and potential benefits of therapies to treat HIV.

"The treatment of HIV has come a long way, but it is essential that we continue to pursue effective novel treatment strategies that minimize toxicity while maximizing tolerability and convenience to meet our objective of delivering advances in care and treatment for all people living with HIV," ViiV Healthcare CEO Dominique Limet said.